Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. Kjeldsen JW, et al. Among authors: martinenaite e. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9. Nat Med. 2021. PMID: 34887574 Free PMC article. Clinical Trial.
Spontaneous presence of FOXO3-specific T cells in cancer patients.
Larsen SK, Ahmad SM, Idorn M, Met Ö, Martinenaite E, Svane IM, Straten PT, Andersen MH. Larsen SK, et al. Among authors: martinenaite e. Oncoimmunology. 2014 Nov 14;3(8):e953411. doi: 10.4161/21624011.2014.953411. eCollection 2014. Oncoimmunology. 2014. PMID: 25960934 Free PMC article.
CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment.
Martinenaite E, Munir Ahmad S, Hansen M, Met Ö, Westergaard MW, Larsen SK, Klausen TW, Donia M, Svane IM, Andersen MH. Martinenaite E, et al. Oncoimmunology. 2016 Sep 30;5(11):e1238541. doi: 10.1080/2162402X.2016.1238541. eCollection 2016. Oncoimmunology. 2016. PMID: 27999757 Free PMC article.
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.
Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH. Ahmad SM, et al. Among authors: martinenaite e. Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018. Oncoimmunology. 2017. PMID: 29308318 Free PMC article.
Frequent adaptive immune responses against arginase-1.
Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, Met Ö, Donia M, Svane IM, Andersen MH. Martinenaite E, et al. Oncoimmunology. 2017 Dec 26;7(3):e1404215. doi: 10.1080/2162402X.2017.1404215. eCollection 2018. Oncoimmunology. 2017. PMID: 29399404 Free PMC article.
29 results